Gimv
VC Fund
Antwerpen, Belgium
Gimv is a European investment company with over three decades of experience in private equity and venture capital. Gimv is listed on NYSE Euronext Brussels. Gimv currently manages around 1.8 billion EUR (including third party funds) of investments in 85 portfolio companies, which jointly realize a turnover of more than EUR 6 billion and employ over 28,000 professionals.
- Total investments:
- 171
- Last investment:
- Lead investor:
- 32%
- Fund size:
- $838M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Gimv invests in
Stages Gimv invests in
Countries Gimv invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 17 contacts → | |||
Round size
- Series A
- $3.3M–$79M
- Series B
- $10M–$73M
- Private Equity
- $8.7M–$82M
Investment Focus
Industry
- Biotechnology 42 (25%)
- Health Care 34 (20%)
- Medical 21 (12%)
- Software 18 (11%)
- Manufacturing 17 (10%)
Stage
- Series B 38 (22%)
- Series A 25 (15%)
- Private Equity 25 (15%)
- Funding Round 20 (12%)
- Series C 19 (11%)
Country
- Belgium 27 (16%)
- United States 24 (14%)
- France 18 (11%)
- The Netherlands 16 (9%)
- Germany 10 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andreas Jurgeit
Partner
|
Partner | Total investments: 5 | Find email | |
Anne Caron
Partner
|
Partner | Total investments: 0 | Find email | |
Arie Hooimeijer
Partner
|
Partner | Total investments: 2 | Find email | |
Bram Vanparys
Partner
|
Partner | Total investments: 6 | Find email | |
Clemence Robles
Principal
|
Principal | Total investments: 0 | Find email | |
| See all 17 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium. | $14.1M / Post-IPO Equity / May 06, 2026 | ||
| exciva is a Provider of targeted drug rescue program intended to involve pharmaceutical research and development based in Heidelberg, Germany. The company's program has been formulated for developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations and methods of making and using suchcompositions, enabling the healthcare industry to access their program for rescuing and reusing approved drugs for new indications and new uses. | $62.2M / Series B / Jan 20, 2026 | ||
Kinaset Therapeutics
|
Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts. | $103M / Series B / Jan 10, 2026 | |
| FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices. | $120M / Series B / Jan 07, 2025 | ||
| Kivu Bioscience is a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class therapeutics and focused on rapidly advancing next generation transformative assets. | $92M / Series A / Oct 28, 2024 | ||
| ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease. | $11M / Series C / Sep 17, 2024 | ||
| Curana is a manufacturer of bike equipment and accessories. | Private Equity / Jul 02, 2024 | ||
| Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI). | $21.9M / Post-IPO Equity / Mar 20, 2024 | ||
| Onera Health is a leader in transforming sleep medicine and remote monitoring. Their breakthrough diagnostic solutions and services are poised to help millions of people struggling with sleep-related ailments while also impacting other medical fields by monitoring various chronic conditions, ultimately improving the health and quality of life ofpatients worldwide. The company’s innovative solutions provide comprehensive sleep test data to physicians in a variety of clinical and non-clinical environments to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the US. | $32.6M / Series C / Jan 16, 2024 | ||
| Citymesh delivers state-of-the-art connectivity. As operator and integrator, we have been planning, installing and maintaining high-end networks in Belgium for fifteen years. Next to our networks, we offer complimentary innovative solutions to reach the next level in every market we serve. The company was a City-WiFi pioneer and now focuses onleveraging its infrastructure with smart solutions such as sensor analysis, footfall analytics and small-cell LTE deployments, integrated into a central cloud-based city management tool. | Private Equity / Jan 01, 2024 | ||
| See all 171 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Gimv invest in?
Gimv invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 171 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Gimv invest in?
Gimv typically joins rounds of $3.3M–$79M at Series A, $10M–$73M at Series B and $8.7M–$82M at Private Equity. These are whole funding-round sizes, not Gimv's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Gimv took part in.
How do I contact Gimv?
Public channels for Gimv include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Gimv?
The team at Gimv includes Andreas Jurgeit (Partner), Anne Caron (Partner) and Arie Hooimeijer (Partner), among 17 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
